The campaign highlights the crossover that Lilly sees between its own 150 years of working toward scientific progress and the ...

Eli Lilly reports fourth-quarter earnings and revenue that handily top expectations and issues solid guidance.

The market for obesity drugs may soon reach almost $100 billion.

Eli Lilly rated SELL: rich valuation priced for perfection, rising GLP-1 competition, pricing pressure, and patent-cliff risk. Click here to read more on LLY stock.

The Indianapolis-based drugmaker reported revenue of $19.3 billion — up 43% from the same period a year ago, driven by growth ...

Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is ...

One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of ...

The stock price has climbed in the triple digits over three years.

Eli Lilly has surged 47% since my last article, exceeding my previous $800 price target and reaching all-time highs near $1,030. LLY's leadership in the obesity treatment market continues to drive top ...

The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) has ...